Skip to main content

02-07-2024 | Multiple Sclerosis | News

EAN 2024

Ocrelizumab is also an effective long-term treatment, particularly for relapsing multiple sclerosis Ocrelizumab is a second-line drug in relapsing multiple sclerosis (RMS) and is also registered for the treatment of primary progressive multiple sclerosis (PPMS). Until now, data on efficacy and long-term safety came from open-label extension studies of RCTs, but now real-world data are also available.

Related topics